Skip to content

Celldex Therapeutics

US · CLDX #2630 by market cap Listed 1970
27.42 -0.54 -1.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Quant vs Street three independent views, side by side

StockVane factor grade
C+
Momentum strategy signal
Sell
Analyst consensus
Buy

Signals diverge - worth digging into why.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

✦ Quant Analyst Revision Trend how this is computed

Mixed
1
■ Upgrades■ Downgrades
  • 1 upgrade vs 0 downgrades among tracked analyst rating changes.
  • Most recent: Barclays moved from Sell to Buy on 2026-04-20.

Analyst consensus 11 analysts

Buy
Avg price target 67.18 +145.0%
Price target rangecurrent 27.42
Low29.00
Avg67.18
High100.00
Buy 91% Hold 9% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-09 CCORF -- Buy 68.00
2026-11-09 Morgan Stanley -- Buy 61.00
2026-11-06 Stifel -- Buy 68.00
2026-11-06 Goldman Sachs -- Hold 29.00
2026-11-06 Guggenheim -- Buy 100.00
2026-11-06 H.C. Wainwright -- Buy 64.00
2026-11-06 Barclays -- Buy 53.00
2026-11-05 Cantor Fitzgerald -- Buy 72.00
2026-10-20 Morgan Stanley -- Buy 57.00
2026-10-15 Wells Fargo -- Buy 72.00
2026-10-13 Cantor Fitzgerald -- Buy 72.00
2026-10-05 H.C. Wainwright -- Buy 64.00
2026-10-03 LifeSci Capital -- Buy 64.00
2026-10-02 H.C. Wainwright -- Buy 64.00
2026-09-28 LifeSci Capital -- Buy 64.00
2026-09-26 LifeSci Capital -- Buy 56.00
2026-09-23 CCORF -- Buy 60.00
2026-09-23 Wells Fargo -- Buy 72.00
2026-09-23 Morgan Stanley -- Buy 57.00
2026-09-23 Leerink Partners -- Buy 88.00
2026-09-23 H.C. Wainwright -- Buy 64.00
2026-09-22 Morgan Stanley -- Buy 57.00
2026-09-22 Stifel -- Buy 68.00
2026-09-22 Guggenheim -- Buy 100.00
2026-09-22 H.C. Wainwright -- Buy 64.00

Price target trend monthly average, last 3 years

Recent rating changes

DateFirmChangeTarget
2026-04-20 Barclays Sell → Buy 45.00

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2023/Q4 2024-02-26 After close ±16.09% +5.83% (in line)
2021/Q4 2022-02-28 After close ±17.30% +5.62% (in line)
2020/Q2 2020-08-06 -- ±33.39% -4.87% (in line)
2019/Q2 2019-08-07 After close -- +2.31%
2018/Q4 2019-03-07 After close -- +10.87%
2018/Q2 2018-08-08 After close -- -6.76%
2017/Q4 2018-03-07 -- -- +11.34%
2017/Q2 2017-08-08 -- -- -1.17%
2016/Q4 2017-03-14 After close -- +3.33%
2016/Q2 2016-08-08 -- -- -3.00%
2015/Q4 2016-02-25 -- -- +0.58%
2015/Q2 2015-08-10 After close -- -20.56%

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Celldex Therapeutics discussion 0 comments

Add a comment